Breaking News Instant updates and real-time market news.

AERI

Aerie Pharmaceuticals

$55.50

1.3 (2.40%)

06:32
07/31/17
07/31
06:32
07/31/17
06:32

Aerie Pharmaceuticals enters research collaboration agreement with DSM

Aerie Pharmaceuticals announced that it has entered into a collaborative research, development and license agreement with DSM. The research collaboration agreement includes an option to license DSM's bioerodible polymer implant technology for evaluating its application to the delivery of certain Aerie compounds, initially focused on retinal diseases. DSM's technology uses polyesteramide polymers (PEA) to produce an injectable, thin fiber that is minute in size. Preclinical experiments have demonstrated early success in conjunction with Aerie compounds, including demonstration of linear sustained elution rates over several months and achievement of target retinal drug concentrations. Aerie previously reported data on Aerie-owned small molecule preclinical product candidate AR-13154, which inhibits Rho kinase and Protein kinase C and thus addresses vascular dysfunction, fibrosis, and inflammation. This molecule has generated lesion size decreases in a preclinical model of wet AMD at levels similar to the market-leading wet AMD anti-VEGF product, and has generated meaningful incremental lesion size reduction when added adjunctively to the anti-VEGF product. Preclinical studies also demonstrated the promising potential of this molecule to reduce neovascularization in a model of proliferative diabetic retinopathy. Pending additional studies, AR-13154 and related compounds may have the potential to provide an entirely new mechanism and pathway to treat these diseases. The terms of the agreement with DSM were not disclosed and the agreement is immaterial to Aerie based on the level of current financial commitments.

  • 28

    Feb

AERI Aerie Pharmaceuticals
$55.50

1.3 (2.40%)

04/13/17
HCWC
04/13/17
NO CHANGE
Target $42
HCWC
Buy
Aerie pullback on hyperemia increase an overreaction, says H.C. Wainwright
H.C. Wainwright analyst Corey Davis said despite the "positive" safety and efficacy data Aerie Pharmaceuticals' reported from its trial of Rhopressa, "focus for the Street" was clearly on the 48% hyperemia rate and 31% discontinuation rate. However, the rate of events outside of hyperemia is relatively comparable to that seen with approved products Lumigan and Travatan and mild redness is likely of little real-world concern in a condition as serious as glaucoma, he tells investors. The analyst, who sees the first-read response in the shares as an overreaction, has a Buy rating and $69 price target on Aerie shares, which are down about 1% to $42 in pre-market trading after suffering a sharper decline in after-market trading last night.
05/25/17
COWN
05/25/17
NO CHANGE
Target $100
COWN
Outperform
Aerie Pharmaceuticals probability of a takeout increasing, says Cowen
Cowen analyst Tyler Van Buren noted the Aerie Pharmaceuticals Roclatan trial was successful and appears approvable as the first FDA approved prostaglandin product. He also noted its Rhopressa drug which is also under review appears approvable as well and combined, the drugs represent a $1.5B long duration opportunity. The analyst believes Aerie is a prime consolidation candidate and said it is not unreasonable to put a 4x multiple on peak sales of $1.5B arrives at a $130-$140 per shares valuation. Van Buren reiterated his Outperform rating and raised his price target to $100 from $70 on Aerie Pharmaceuticals shares.
05/25/17
NEED
05/25/17
NO CHANGE
Target $65
NEED
Buy
Aerie Pharmaceuticals price target raised to $65 from $58 at Needham
Needham analyst Serge Belanger raised his price target for Aerie Pharmaceuticals to $65 saying the company reported positive results from Mercury-2, the second of two Phase 3 trials evaluating Roclatan as treatment for glaucoma. Once again, Roclatan met all its endpoints, Belanger tells investors in a research note. The data are a "key derisking event" for the program, the analyst adds. He keeps a Buy rating on Aerie.
07/03/17
ADAM
07/03/17
NO CHANGE
Target $65
ADAM
Buy
Aerie price target raised to $65 from $60 at Canaccord
Canaccord analyst Dewey Steadman said he remains confident in Aerie Pharmaceuticals' ability to launch Rhopressa as early at the first half of next year, noting that the company is preparing for an FDA advisory committee meeting that could happen before Thanksgiving. Steadman, who sees Rhopressa as a $500M product at its peak, also said he's confident in a potential Roclatan approval in 2019, stating that could be a $1B product. The analyst keeps a Buy rating on Aerie shares and raised his price target on the stock to $65 from $60.

TODAY'S FREE FLY STORIES

10:30
11/23/17
11/23
10:30
11/23/17
10:30
General news
FX Action: EUR-USD, USD-JPY and other major pairings are in sideways mode »

FX Action: EUR-USD,…

DE

Deere

$145.25

6.02 (4.32%)

09:53
11/23/17
11/23
09:53
11/23/17
09:53
Upgrade
Deutsche Bank gets off sidelines, upgrades Deere shares to Buy »

Deutsche Bank analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

08:55
11/23/17
11/23
08:55
11/23/17
08:55
General news
FX Update: USD-CAD vaulted upwards on weak Canadian data »

FX Update: USD-CAD…

08:30
11/23/17
11/23
08:30
11/23/17
08:30
General news
FX Action: The USD index (DXY) logged a one-month low »

FX Action: The USD index…

TSLA

Tesla

$312.60

-5.21 (-1.64%)

08:08
11/23/17
11/23
08:08
11/23/17
08:08
Hot Stocks
Tesla CEO highlights 'record time' on Australian ion battery »

Tesla CEO Elon Musk…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

TSLA

Tesla

$312.60

-5.21 (-1.64%)

08:07
11/23/17
11/23
08:07
11/23/17
08:07
Hot Stocks
Tesla completes construction on largest lithium ion battery in Australia »

The South Australian…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

GSK

GlaxoSmithKline

$35.06

0.25 (0.72%)

, INVA

Innoviva

$13.42

0.01 (0.07%)

07:56
11/23/17
11/23
07:56
11/23/17
07:56
Hot Stocks
GSK, Innoviva submit data to FDA for expanded Trelegy Ellipta label »

GlaxoSmithKline (GSK) and…

GSK

GlaxoSmithKline

$35.06

0.25 (0.72%)

INVA

Innoviva

$13.42

0.01 (0.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SVM

Silvercorp Metals

$2.51

-0.07 (-2.71%)

07:52
11/23/17
11/23
07:52
11/23/17
07:52
Hot Stocks
Silvercorp Metals to buy back up to 5% of shares »

Silvercorp Metals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CEL

Cellcom Israel

$10.00

-0.1 (-0.99%)

07:49
11/23/17
11/23
07:49
11/23/17
07:49
Hot Stocks
Cellcom Israel now second layer company according to Concentration Law »

Cellcom Israel announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GASS

StealthGas

$4.07

0.36 (9.70%)

07:06
11/23/17
11/23
07:06
11/23/17
07:06
Recommendations
StealthGas analyst commentary at Jefferies »

StealthGas trades at only…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CPRT

Copart

$41.01

4.31 (11.74%)

07:02
11/23/17
11/23
07:02
11/23/17
07:02
Recommendations
Copart analyst commentary at Jefferies »

Copart price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

DE

Deere

$145.25

6.02 (4.32%)

06:56
11/23/17
11/23
06:56
11/23/17
06:56
Upgrade
Deere rating change at Deutsche Bank »

Deere upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

DE

Deere

$145.25

6.02 (4.32%)

06:55
11/23/17
11/23
06:55
11/23/17
06:55
Recommendations
Deere analyst commentary at Wells Fargo »

Deere price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

06:40
11/23/17
11/23
06:40
11/23/17
06:40
General news
FX Update: The dollar has remained on a weakening track »

FX Update: The dollar has…

SECO

Seeco Holding

$8.34

0.14 (1.71%)

04:55
11/23/17
11/23
04:55
11/23/17
04:55
Conference/Events
Seeco Holding management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Nov

04:55
11/23/17
11/23
04:55
11/23/17
04:55
Conference/Events
Deutsche Bank to hold a conference »

Thailand SET Corporate…

04:55
11/23/17
11/23
04:55
11/23/17
04:55
Conference/Events
RBC Capital to hold field trip »

European Utilities Field…

BASFY

BASF

$27.39

-0.13 (-0.47%)

04:55
11/23/17
11/23
04:55
11/23/17
04:55
Conference/Events
BASF management to meet with Evercore ISI »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Nov

  • 24

    Nov

RBS

RBS

$7.30

-0.04 (-0.54%)

04:55
11/23/17
11/23
04:55
11/23/17
04:55
Conference/Events
RBS management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Nov

  • 24

    Nov

04:25
11/23/17
11/23
04:25
11/23/17
04:25
General news
FX Action: USD-CAD punched out a 10-day low »

FX Action: USD-CAD…

02:35
11/23/17
11/23
02:35
11/23/17
02:35
General news
FX Update: The dollar has remained on a downward path »

FX Update: The dollar…

L

Loews

$49.36

-0.02 (-0.04%)

, GE

General Electric

$18.15

0.32 (1.79%)

18:41
11/22/17
11/22
18:41
11/22/17
18:41
Hot Stocks
Loews CEO James Tisch buys 3M shares of General Electric »

In a regulatory filing,…

L

Loews

$49.36

-0.02 (-0.04%)

GE

General Electric

$18.15

0.32 (1.79%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BRFS

BRF S.A.

$12.77

-0.16 (-1.24%)

18:06
11/22/17
11/22
18:06
11/22/17
18:06
Hot Stocks
BRF S.A. names Jose Aurelio Drummond Jr. as CEO »

BRF S.A. hereby informs…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SU

Suncor

$35.42

0.2 (0.57%)

18:02
11/22/17
11/22
18:02
11/22/17
18:02
Hot Stocks
Suncor closes sale of equity interest in East Tan Farm, redeems $750M in debt »

Suncor successfully…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

SAP

SAP

$113.85

-1.44 (-1.25%)

17:53
11/22/17
11/22
17:53
11/22/17
17:53
Periodicals
SAP launches investigation of sales practices in Gulf region, Reuters reports »

SAP has launched a formal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.